| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2020: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2019: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2018: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
|
|---|
| Outline of Final Research Achievements |
In this project, we focused on the mitochondrial respiratory chain as a possible vulnerability specific to glioma stem cells. The results revealed that the expression levels of the components of the respiratory chain encoded by the mitochondrial DNA were increased in glioma stem cells compared to their differentiated counterparts and that glioma stem cells were dependent on the respiratory chain for their survival. We then screened a panel of approved drugs known to inhibit the function of the respiratory chain, and successfully identified verteporfin, a therapeutic agent for age-related macular degeneration, as a glioma stem cell-specific drug that can induce extensive cell death in glioma stem cells while sparing their differentiated counterparts or normal cells.
|
